サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1550125

線維筋痛症治療市場：世界の産業分析、規模、シェア、成長、動向、予測、2024-2033年

Fibromyalgia Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033
出版日: | 発行: Persistence Market Research | ページ情報: 英文 231 Pages | 納期: 2～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.96円
線維筋痛症治療市場：世界の産業分析、規模、シェア、成長、動向、予測、2024-2033年
出版日: 2024年09月05日
発行: Persistence Market Research
ページ情報: 英文 231 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Research社はこのほど、世界の線維筋痛症治療市場に関する広範なレポートを発行しました。当レポートでは、市場促進要因・動向・機会・課題などの主要な市場力学を包括的に分析し、市場構造に関する深い洞察を提供しています。

主要な洞察

  • 線維筋痛症治療市場規模（2024E）：15億米ドル
  • 予測市場規模（2033F）：27億米ドル
  • 世界市場成長率（CAGR 2024年から2033年まで）：6.7%

線維筋痛症治療市場：調査範囲

線維筋痛症治療市場は、広範な筋骨格痛、疲労、認知障害を特徴とする慢性疾患を管理するために使用される幅広い治療アプローチを包含します。線維筋痛症は世界中で数百万人が罹患しており、その管理には多くの場合、薬物療法、理学療法、生活習慣の改善が必要です。同市場は、病院、専門クリニック、リハビリセンターなど、複数のセグメントにサービスを提供しています。成長の原動力は、線維筋痛症に対する認識の高まり、治療法の進歩、さまざまな医療現場における症状管理のための集学的アプローチの利用拡大です。

市場成長の促進要因：

線維筋痛症治療の世界市場を牽引している主な要因はいくつかあります。線維筋痛症の罹患率が世界的に上昇しているため、この症状に対する効果的な治療を求める患者が増え、市場の成長を後押ししています。新しい医薬製剤、非薬物療法、遠隔医療アプリケーションなどの治療オプションにおける技術的進歩は、線維筋痛症管理の有効性とアクセシビリティを向上させ、市場拡大をさらに後押ししています。さらに、早期診断の重要性と個別化治療計画の策定に対する意識の高まりが需要を促進しています。革新的な薬物療法の導入に伴う研究開発活動の強化は、さまざまな症状プロファイルを持つ患者に対してよりオーダーメイドのソリューションを提供することで、市場の成長に寄与しています。

市場抑制要因：

有望な成長が見込まれるもの、線維筋痛症治療市場は、先進治療の高額な費用や病態の正確な診断の複雑さに関連する課題に直面しています。地域によっては専門的な治療へのアクセスが限られていることや、非侵襲的であることから一部の患者に好まれるホリスティック医療や補完医療などの代替治療が利用可能であることが、市場の成長を阻害する可能性があります。さらに、この疾患の慢性的な性質と治療法の欠如は、長期的な管理に継続的な課題をもたらします。これらの問題に対処するためには、線維筋痛症の根本的な原因をよりよく理解し、治療の有効性、手頃な価格、利用しやすさを改善するための調査への継続的な投資が必要です。

市場機会：

本市場は、患者の転帰を改善する集学的治療アプローチの採用増加により、大きなビジネスチャンスをもたらしています。新規クラスの抗うつ薬、抗けいれん薬、筋弛緩薬などの新薬療法の開発は、より効果的な症状管理に対するニーズの高まりに対応しています。新興市場におけるヘルスケア・インフラの拡大は、市場成長のための新たなチャネルを提供し、企業はより多くの患者集団にリーチし、最先端治療へのアクセスを提供することができます。戦略的パートナーシップ、患者教育プログラムへの投資、遠隔管理のための遠隔医療プラットフォームのイントロダクションは、新たな機会を活用し、市場でのリーダーシップを維持するために不可欠です。

本レポートで扱う主な質問

  • 線維筋痛症治療市場の世界的成長を促進する主な要因は何か？
  • 様々なヘルスケア環境において、どのタイプの治療が採用をリードしているか？
  • 技術の進歩は線維筋痛症治療市場の競合情勢にどのような影響を与えているか？
  • 線維筋痛症治療市場の主要プレイヤーは誰で、競争力を維持するためにどのような戦略を採用しているのか？
  • 世界の線維筋痛症治療市場の新たな動向と将来展望は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲/ 分類
  • 市場の定義/ 範囲/ 制限
  • 包含と除外

第3章 主要な市場動向

  • 市場に影響を与える主な動向
  • 医薬品クラスのイノベーション/開発動向

第4章 重要成功要因

  • 薬物クラスの採用分析
  • 主な規制
  • 最近の医薬品クラスの発売/承認
  • PESTEL分析
  • パイプライン評価
  • 主要プレーヤーによる主要なプロモーション戦略
  • ポーターの分析
  • バリューチェーン分析

第5章 市場背景

  • マクロ経済要因
  • 予測要因- 関連性と影響
  • 市場力学

第6章 COVID-19危機分析

  • COVID-19と影響分析
    • 薬剤クラス別
    • 流通チャネル別
    • 国別
  • 2022年の市場シナリオ

第7章 世界の線維筋痛症治療市場の需要（価値または規模、10億米ドル）分析

  • 市場金額（10億米ドル）分析、2019～2023年
  • 市場金額（10億米ドル）予測、2024～2033年
    • 前年比成長動向分析
    • 絶対的収益機会

第8章 世界の線維筋痛症治療市場分析：薬剤クラス別

  • イントロダクション/主な調査結果
  • 市場規模（10億米ドル）分析、2019～2023年
  • 市場規模（10億米ドル）分析と予測、2024～2033年
    • 抗うつ薬
      • ベンラファキシン
      • デュロキセチン塩酸塩
      • ミルナシプラン塩酸塩
      • その他
    • 抗けいれん薬
      • プレガバリン
      • ガバペンチン
      • その他
    • 筋弛緩剤
    • 鎮痛剤
  • 薬剤クラス別の市場の魅力分析

第9章 世界の線維筋痛症治療市場分析：流通チャネル別

  • イントロダクション/主な調査結果
  • 市場規模（10億米ドル）分析、2019～2023年
  • 市場規模（10億米ドル）分析と予測、2024～2033年
    • 病院薬局
    • ドラッグストア
    • 小売薬局
    • オンライン薬局
  • 流通チャネル別市場の魅力分析

第10章 世界の線維筋痛症治療市場分析：地域別

  • イントロダクション
  • 市場規模（10億米ドル）分析、2019～2023年
  • 市場規模（10億米ドル）分析と予測、2024～2033年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東およびアフリカ（中東・アフリカ）
  • 地域別市場の魅力分析

第11章 北米の線維筋痛症治療市場分析

第12章 ラテンアメリカの線維筋痛症治療市場分析

第13章 欧州の線維筋痛症治療市場分析

第14章 東アジアの線維筋痛症治療市場分析

第15章 南アジアの線維筋痛症治療市場分析

第16章 オセアニアの線維筋痛症治療市場

第17章 中東およびアフリカの線維筋痛症治療市場分析

第18章 市場構造分析

  • 企業階層別市場分析
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第19章 競合分析

  • 競合ダッシュボード
  • 競合の詳細
    • FSD Pharma
    • Pfizer, Inc.
    • Eli Lilly and Company
    • AbbVie, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Johnson &Johnson Services, Inc
    • Sanofi
    • GlaxoSmithKline plc.
    • Bayer AG
    • TONIX Pharmaceuticals Holdings Corp
    • Virios Therapeutics, Inc.
    • Aptinyx Inc.

第20章 使用される前提条件と頭字語

第21章 調査手法

目次
Product Code: PMRREP32455

Persistence Market Research has recently published an extensive report on the global Fibromyalgia Treatment Market. This report offers a comprehensive analysis of the key market dynamics, including drivers, trends, opportunities, and challenges, providing deep insights into the market structure.

Key Insights:

  • Fibromyalgia Treatment Market Size (2024E): USD 1.5 Billion
  • Projected Market Value (2033F): USD 2.7 Billion
  • Global Market Growth Rate (CAGR 2024 to 2033): 6.7%

Fibromyalgia Treatment Market - Report Scope:

The Fibromyalgia Treatment Market encompasses a wide range of therapeutic approaches used to manage the chronic condition characterized by widespread musculoskeletal pain, fatigue, and cognitive disturbances. Fibromyalgia affects millions worldwide, and its management often involves medications, physical therapy, and lifestyle changes. The market serves multiple segments, including hospitals, specialty clinics, and rehabilitation centers. Growth is driven by the increasing awareness of fibromyalgia, advancements in therapeutic treatments, and the expanding use of multidisciplinary approaches for symptom management across various healthcare settings.

Market Growth Drivers:

Several key factors are driving the global Fibromyalgia Treatment Market. The rising incidence of fibromyalgia globally is boosting the market's growth as more patients seek effective treatments for this condition. Technological advancements in treatment options, such as new pharmaceutical formulations, non-drug therapies, and telehealth applications, have improved the efficacy and accessibility of fibromyalgia management, further fueling market expansion. Additionally, growing awareness of the importance of early diagnosis and the development of personalized treatment plans is driving demand. Enhanced research and development activities, along with the introduction of innovative drug therapies, contribute to market growth by offering more tailored solutions for patients with varying symptom profiles.

Market Restraints:

Despite promising growth prospects, the Fibromyalgia Treatment Market faces challenges related to the high costs of advanced therapies and the complexities of accurately diagnosing the condition. Market growth can be hindered by limited access to specialized care in certain regions and the availability of alternative treatments such as holistic or complementary medicine, which may be preferred by some patients due to their non-invasive nature. Additionally, the chronic nature of the condition and the lack of a cure present ongoing challenges for long-term management. Addressing these issues requires continued investment in research to better understand the underlying causes of fibromyalgia and to improve treatment efficacy, affordability, and accessibility.

Market Opportunities:

The market presents significant opportunities driven by the increasing adoption of multidisciplinary treatment approaches, which offer improved patient outcomes. The development of new drug therapies, including novel classes of antidepressants, anticonvulsants, and muscle relaxants, caters to the growing need for more effective symptom management. The expansion of healthcare infrastructure in emerging markets provides new channels for market growth, allowing companies to reach a broader patient population and offer access to cutting-edge treatments. Strategic partnerships, investments in patient education programs, and the introduction of telemedicine platforms for remote management are essential for capitalizing on emerging opportunities and maintaining market leadership.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the Fibromyalgia Treatment Market globally?
  • Which types of treatments are leading the adoption in various healthcare settings?
  • How are technological advancements influencing the competitive landscape of the Fibromyalgia Treatment Market?
  • Who are the key players in the Fibromyalgia Treatment Market, and what strategies are they employing to stay competitive?
  • What are the emerging trends and future prospects in the global Fibromyalgia Treatment Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Fibromyalgia Treatment Market, including Pfizer, Inc., Eli Lilly and Company, and Teva Pharmaceuticals, focus on innovation, product differentiation, and strategic collaborations to gain a competitive edge. These companies invest in R&D to develop advanced drug formulations and explore non-drug therapies. Collaborations with healthcare providers, research institutions, and technology developers facilitate market access and promote new treatment adoption. Emphasis on patient education, high-quality treatments, and comprehensive support programs fosters market growth and enhances brand loyalty in the evolving Fibromyalgia Treatment Market landscape.

Key Companies Profiled:

  • FSD Pharma
  • Pfizer, Inc.
  • Eli Lilly and Company
  • AbbVie, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson Services, Inc
  • Sanofi
  • GlaxoSmithKline plc.
  • Bayer AG
  • TONIX Pharmaceuticals Holdings Corp
  • Virios Therapeutics, Inc.
  • Aptinyx Inc.

Fibromyalgia Treatment Market Industry Segmentation:

Drug Class:

  • Antidepressants
  • Anticonvulsants
  • Muscle Relaxants
  • Analgesics

Distribution Channel:

  • Hospitals Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Online Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Drug Class Innovation / Development Trends

4. Key Success Factors

  • 4.1. Drug Class Adoption Analysis
  • 4.2. Key Regulations
  • 4.3. Recent Drug Class launches/ Approvals
  • 4.4. PESTEL Analysis
  • 4.5. Pipeline Assessment
  • 4.6. Key Promotional Strategies, By Key Players
  • 4.7. Porter's Analysis
  • 4.8. Value Chain Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Outlook
    • 5.1.3. Global Musculoskeletal Disorder drugs market
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Increase in R&D Spending
    • 5.2.2. Growing Disease Prevalence
    • 5.2.3. Cost of Drug Class
    • 5.2.4. Drug Class Features
    • 5.2.5. New Drug Class approvals
    • 5.2.6. Drug Class Pipeline
    • 5.2.7. Changes in Regulatory Policies
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Drug Class
    • 6.1.2. By Distribution Channel
    • 6.1.3. By Country
  • 6.2. 2022 Market Scenario

7. Global Fibromyalgia Treatment Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

  • 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Fibromyalgia Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Drug Class

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Bn) Analysis By Drug Class, 2019-2023
  • 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Drug Class, 2024-2033
    • 8.3.1. Antidepressants
      • 8.3.1.1. Venlafaxine
      • 8.3.1.2. Duloxetine HCl
      • 8.3.1.3. Milnacipran HCl
      • 8.3.1.4. Others
    • 8.3.2. Anticonvulsants
      • 8.3.2.1. Pregabalin
      • 8.3.2.2. Gabapentin
      • 8.3.2.3. Others
    • 8.3.3. Muscle Relaxants
    • 8.3.4. Analgesics
  • 8.4. Market Attractiveness Analysis By Drug Class

9. Global Fibromyalgia Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channel

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2023
  • 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2024-2033
    • 9.3.1. Hospitals Pharmacies
    • 9.3.2. Drug Stores
    • 9.3.3. Retail Pharmacies
    • 9.3.4. Online Pharmacies
  • 9.4. Market Attractiveness Analysis By Distribution Channel

10. Global Fibromyalgia Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Region

  • 10.1. Introduction
  • 10.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
  • 10.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2024-2033
    • 10.3.1. North America
    • 10.3.2. Latin America
    • 10.3.3. Europe
    • 10.3.4. East Asia
    • 10.3.5. South Asia
    • 10.3.6. Oceania
    • 10.3.7. Middle East and Africa (MEA)
  • 10.4. Market Attractiveness Analysis By Region

11. North America Fibromyalgia Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 11.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 11.3.1. By Country
      • 11.3.1.1. U.S.
      • 11.3.1.2. Canada
    • 11.3.2. By Drug Class
    • 11.3.3. By Distribution Channel
  • 11.4. Market Attractiveness Analysis
    • 11.4.1. By Country
    • 11.4.2. By Drug Class
    • 11.4.3. By Distribution Channel
  • 11.5. Market Trends
  • 11.6. Drivers and Restraints - Impact Analysis
  • 11.7. Key Players - Intensity Mapping
  • 11.8. Country Level Analysis & Forecast
    • 11.8.1. U.S. Fibromyalgia Treatment Market Analysis
      • 11.8.1.1. Introduction
      • 11.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 11.8.1.2.1. By Drug Class
        • 11.8.1.2.2. By Distribution Channel
    • 11.8.2. Canada Fibromyalgia Treatment Market Analysis
      • 11.8.2.1. Introduction
      • 11.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 11.8.2.2.1. By Drug Class
        • 11.8.2.2.2. By Distribution Channel

12. Latin America Fibromyalgia Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 12.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 12.3.1. By Country
      • 12.3.1.1. Mexico
      • 12.3.1.2. Brazil
      • 12.3.1.3. Argentina
      • 12.3.1.4. Rest of Latin America
    • 12.3.2. By Drug Class
    • 12.3.3. By Distribution Channel
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Drug Class
    • 12.4.3. By Distribution Channel
  • 12.5. Market Trends
  • 12.6. Drivers and Restraints - Impact Analysis
  • 12.7. Key Players - Intensity Mapping
  • 12.8. Country Level Analysis & Forecast
    • 12.8.1. Mexico Fibromyalgia Treatment Market Analysis
      • 12.8.1.1. Introduction
      • 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.1.2.1. By Drug Class
        • 12.8.1.2.2. By Distribution Channel
    • 12.8.2. Brazil Fibromyalgia Treatment Market Analysis
      • 12.8.2.1. Introduction
      • 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.2.2.1. By Drug Class
        • 12.8.2.2.2. By Distribution Channel
    • 12.8.3. Argentina Fibromyalgia Treatment Market Analysis
      • 12.8.3.1. Introduction
      • 12.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.3.2.1. By Drug Class
        • 12.8.3.2.2. By Distribution Channel

13. Europe Fibromyalgia Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 13.3.1. By Country
      • 13.3.1.1. Germany
      • 13.3.1.2. Italy
      • 13.3.1.3. France
      • 13.3.1.4. U.K.
      • 13.3.1.5. Spain
      • 13.3.1.6. BENELUX
      • 13.3.1.7. Russia
      • 13.3.1.8. Rest of Europe
    • 13.3.2. By Drug Class
    • 13.3.3. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Drug Class
    • 13.4.3. By Distribution Channel
  • 13.5. Market Trends
  • 13.6. Drivers and Restraints - Impact Analysis
  • 13.7. Key Players - Intensity Mapping
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. Germany Fibromyalgia Treatment Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Drug Class
        • 13.8.1.2.2. By Distribution Channel
    • 13.8.2. Italy Fibromyalgia Treatment Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Drug Class
        • 13.8.2.2.2. By Distribution Channel
    • 13.8.3. France Fibromyalgia Treatment Market Analysis
      • 13.8.3.1. Introduction
      • 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.3.2.1. By Drug Class
        • 13.8.3.2.2. By Distribution Channel
    • 13.8.4. U.K. Fibromyalgia Treatment Market Analysis
      • 13.8.4.1. Introduction
      • 13.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.4.2.1. By Drug Class
        • 13.8.4.2.2. By Distribution Channel
    • 13.8.5. Spain Fibromyalgia Treatment Market Analysis
      • 13.8.5.1. Introduction
      • 13.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.5.2.1. By Drug Class
        • 13.8.5.2.2. By Distribution Channel
    • 13.8.6. BENELUX Fibromyalgia Treatment Market Analysis
      • 13.8.6.1. Introduction
      • 13.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.6.2.1. By Drug Class
        • 13.8.6.2.2. By Distribution Channel
    • 13.8.7. Russia Fibromyalgia Treatment Market Analysis
      • 13.8.7.1. Introduction
      • 13.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.7.2.1. By Drug Class
        • 13.8.7.2.2. By Distribution Channel

14. East Asia Fibromyalgia Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 14.3.1. By Country
      • 14.3.1.1. China
      • 14.3.1.2. Japan
      • 14.3.1.3. South Korea
    • 14.3.2. By Drug Class
    • 14.3.3. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Drug Class
    • 14.4.3. By Distribution Channel
  • 14.5. Market Trends
  • 14.6. Drivers and Restraints - Impact Analysis
  • 14.7. Key Players - Intensity Mapping
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. China Fibromyalgia Treatment Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Drug Class
        • 14.8.1.2.2. By Distribution Channel
    • 14.8.2. Japan Fibromyalgia Treatment Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Drug Class
        • 14.8.2.2.2. By Distribution Channel
    • 14.8.3. South Korea Fibromyalgia Treatment Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Drug Class
        • 14.8.3.2.2. By Distribution Channel

15. South Asia Fibromyalgia Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 15.3.1. By Country
      • 15.3.1.1. India
      • 15.3.1.2. Indonesia
      • 15.3.1.3. Malaysia
      • 15.3.1.4. Thailand
      • 15.3.1.5. Rest of South Asia
    • 15.3.2. By Drug Class
    • 15.3.3. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Drug Class
    • 15.4.3. By Distribution Channel
  • 15.5. Market Trends
  • 15.6. Drivers and Restraints - Impact Analysis
  • 15.7. Key Players - Intensity Mapping
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. India Fibromyalgia Treatment Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Drug Class
        • 15.8.1.2.2. By Distribution Channel
    • 15.8.2. Indonesia Fibromyalgia Treatment Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Drug Class
        • 15.8.2.2.2. By Distribution Channel
    • 15.8.3. Malaysia Fibromyalgia Treatment Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Drug Class
        • 15.8.3.2.2. By Distribution Channel
    • 15.8.4. Thailand Fibromyalgia Treatment Market Analysis
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Drug Class
        • 15.8.4.2.2. By Distribution Channel

16. Oceania Fibromyalgia Treatment Market 2019-2023 and Forecast 2024-2033

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 16.3.1. By Country
      • 16.3.1.1. Australia
      • 16.3.1.2. New Zealand
    • 16.3.2. By Drug Class
    • 16.3.3. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Drug Class
    • 16.4.3. By Distribution Channel
  • 16.5. Market Trends
  • 16.6. Drivers and Restraints - Impact Analysis
  • 16.7. Key Players - Intensity Mapping
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. Australia Fibromyalgia Treatment Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Drug Class
        • 16.8.1.2.2. By Distribution Channel
    • 16.8.2. New Zealand Fibromyalgia Treatment Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Drug Class
        • 16.8.2.2.2. By Distribution Channel

17. Middle East and Africa (MEA) Fibromyalgia Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 17.3.1. By Country
      • 17.3.1.1. GCC Countries
      • 17.3.1.2. Turkey
      • 17.3.1.3. North Africa
      • 17.3.1.4. South Africa
      • 17.3.1.5. Rest of Middle East and Africa
    • 17.3.2. By Drug Class
    • 17.3.3. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Drug Class
    • 17.4.3. By Distribution Channel
  • 17.5. Market Trends
  • 17.6. Drivers and Restraints - Impact Analysis
  • 17.7. Key Players - Intensity Mapping
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. GCC Countries Fibromyalgia Treatment Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Drug Class
        • 17.8.1.2.2. By Distribution Channel
    • 17.8.2. Turkey Fibromyalgia Treatment Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Drug Class
        • 17.8.2.2.2. By Distribution Channel
    • 17.8.3. South Africa Fibromyalgia Treatment Market Analysis
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Drug Class
        • 17.8.3.2.2. By Distribution Channel
    • 17.8.4. North Africa Fibromyalgia Treatment Market Analysis
      • 17.8.4.1. Introduction
      • 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.4.2.1. By Drug Class
        • 17.8.4.2.2. By Distribution Channel

18. Market Structure Analysis

  • 18.1. Market Analysis by Tier of Companies
  • 18.2. Market Share Analysis of Top Players
  • 18.3. Market Presence Analysis

19. Competition Analysis

  • 19.1. Competition Dashboard
  • 19.2. Competition Deep Dive
    • 19.2.1. FSD Pharma
      • 19.2.1.1. Overview
      • 19.2.1.2. Product Portfolio
      • 19.2.1.3. Sales Footprint
      • 19.2.1.4. Key Financials
      • 19.2.1.5. SWOT Analysis
      • 19.2.1.6. Strategy Overview
        • 19.2.1.6.1. Marketing Strategy
        • 19.2.1.6.2. Product Strategy
        • 19.2.1.6.3. Channel Strategy
    • 19.2.2. Pfizer, Inc.
      • 19.2.2.1. Overview
      • 19.2.2.2. Product Portfolio
      • 19.2.2.3. Sales Footprint
      • 19.2.2.4. Key Financials
      • 19.2.2.5. SWOT Analysis
      • 19.2.2.6. Strategy Overview
        • 19.2.2.6.1. Marketing Strategy
        • 19.2.2.6.2. Product Strategy
        • 19.2.2.6.3. Channel Strategy
    • 19.2.3. Eli Lilly and Company
      • 19.2.3.1. Overview
      • 19.2.3.2. Product Portfolio
      • 19.2.3.3. Sales Footprint
      • 19.2.3.4. Key Financials
      • 19.2.3.5. SWOT Analysis
      • 19.2.3.6. Strategy Overview
        • 19.2.3.6.1. Marketing Strategy
        • 19.2.3.6.2. Product Strategy
        • 19.2.3.6.3. Channel Strategy
    • 19.2.4. AbbVie, Inc.
      • 19.2.4.1. Overview
      • 19.2.4.2. Product Portfolio
      • 19.2.4.3. Sales Footprint
      • 19.2.4.4. Key Financials
      • 19.2.4.5. SWOT Analysis
      • 19.2.4.6. Strategy Overview
        • 19.2.4.6.1. Marketing Strategy
        • 19.2.4.6.2. Product Strategy
        • 19.2.4.6.3. Channel Strategy
    • 19.2.5. Teva Pharmaceutical Industries Ltd.
      • 19.2.5.1. Overview
      • 19.2.5.2. Product Portfolio
      • 19.2.5.3. Sales Footprint
      • 19.2.5.4. Key Financials
      • 19.2.5.5. SWOT Analysis
      • 19.2.5.6. Strategy Overview
        • 19.2.5.6.1. Marketing Strategy
        • 19.2.5.6.2. Product Strategy
        • 19.2.5.6.3. Channel Strategy
    • 19.2.6. Johnson & Johnson Services, Inc
      • 19.2.6.1. Overview
      • 19.2.6.2. Product Portfolio
      • 19.2.6.3. Sales Footprint
      • 19.2.6.4. Key Financials
      • 19.2.6.5. SWOT Analysis
      • 19.2.6.6. Strategy Overview
        • 19.2.6.6.1. Marketing Strategy
        • 19.2.6.6.2. Product Strategy
        • 19.2.6.6.3. Channel Strategy
    • 19.2.7. Sanofi
      • 19.2.7.1. Overview
      • 19.2.7.2. Product Portfolio
      • 19.2.7.3. Sales Footprint
      • 19.2.7.4. Key Financials
      • 19.2.7.5. SWOT Analysis
      • 19.2.7.6. Strategy Overview
        • 19.2.7.6.1. Marketing Strategy
        • 19.2.7.6.2. Product Strategy
        • 19.2.7.6.3. Channel Strategy
    • 19.2.8. GlaxoSmithKline plc.
      • 19.2.8.1. Overview
      • 19.2.8.2. Product Portfolio
      • 19.2.8.3. Sales Footprint
      • 19.2.8.4. Key Financials
      • 19.2.8.5. SWOT Analysis
      • 19.2.8.6. Strategy Overview
        • 19.2.8.6.1. Marketing Strategy
        • 19.2.8.6.2. Product Strategy
        • 19.2.8.6.3. Channel Strategy
    • 19.2.9. Bayer AG
      • 19.2.9.1. Overview
      • 19.2.9.2. Product Portfolio
      • 19.2.9.3. Sales Footprint
      • 19.2.9.4. Key Financials
      • 19.2.9.5. SWOT Analysis
      • 19.2.9.6. Strategy Overview
        • 19.2.9.6.1. Marketing Strategy
        • 19.2.9.6.2. Product Strategy
        • 19.2.9.6.3. Channel Strategy
    • 19.2.10. TONIX Pharmaceuticals Holdings Corp
      • 19.2.10.1. Overview
      • 19.2.10.2. Product Portfolio
      • 19.2.10.3. Sales Footprint
      • 19.2.10.4. Key Financials
      • 19.2.10.5. SWOT Analysis
      • 19.2.10.6. Strategy Overview
        • 19.2.10.6.1. Marketing Strategy
        • 19.2.10.6.2. Product Strategy
        • 19.2.10.6.3. Channel Strategy
    • 19.2.11. Virios Therapeutics, Inc.
      • 19.2.11.1. Overview
      • 19.2.11.2. Product Portfolio
      • 19.2.11.3. Sales Footprint
      • 19.2.11.4. Key Financials
      • 19.2.11.5. SWOT Analysis
      • 19.2.11.6. Strategy Overview
        • 19.2.11.6.1. Marketing Strategy
        • 19.2.11.6.2. Product Strategy
        • 19.2.11.6.3. Channel Strategy
    • 19.2.12. Aptinyx Inc.
      • 19.2.12.1. Overview
      • 19.2.12.2. Product Portfolio
      • 19.2.12.3. Sales Footprint
      • 19.2.12.4. Key Financials
      • 19.2.12.5. SWOT Analysis
      • 19.2.12.6. Strategy Overview
        • 19.2.12.6.1. Marketing Strategy
        • 19.2.12.6.2. Product Strategy
        • 19.2.12.6.3. Channel Strategy

20. Assumptions and Acronyms Used

21. Research Methodology